Skip to main content

Johnson & Johnson (JNJ)

NYSE: JNJ · IEX Real-Time Price · USD
161.75
+0.45 (0.28%)
After-hours:Oct 15, 2021 7:59 PM EDT
161.30
1.19 (0.74%)
At close: Oct 15, 4:00 PM
Market Cap424.62B
Revenue (ttm)89.19B
Net Income (ttm)17.77B
Shares Out2.63B
EPS (ttm)6.65
PE Ratio24.25
Forward PE15.31
Dividend$4.09 (2.54%)
Ex-Dividend DateAug 23, 2021
Volume6,918,407
Open161.03
Previous Close160.11
Day's Range160.41 - 161.81
52-Week Range130.31 - 178.93
Beta0.72
AnalystsBuy
Price Target188.88 (+17.1%)
Est. Earnings DateOct 19, 2021

About JNJ

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the S...

IndustryPharmaceuticals
IPO DateSep 24, 1944
CEOAlex Gorsky
Employees136,000
Stock ExchangeNYSE
Ticker SymbolJNJ
Full Company Profile

Financial Performance

In 2020, JNJ's revenue was $82.58 billion, an increase of 0.64% compared to the previous year's $82.06 billion. Earnings were $14.71 billion, a decrease of -2.68%.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is 188.88, which is an increase of 17.10% from the latest price.

Price Target
$188.88
(17.10% upside)
Analyst Consensus: Buy

News

Will Johnson & Johnson Win Authorization for Its COVID-19 Booster?

It's highly likely.

15 hours ago - The Motley Fool

The Safest Stocks to Buy if There's a Stock Market Crash

This stock trio is perfectly positioned to help investors navigate a possible downturn.

Other symbols:DUKGOOGGOOGL
16 hours ago - The Motley Fool

What to expect after the FDA's approval of the J&J booster

#J&Jbooster With the FDA's advisory panel unanimously approving booster shots of the J&J vaccine two months after the first dose, Dr. Lakshman Swamy, ICU physician at Cambridge Health Alliance & Boston ...

22 hours ago - Yahoo Finance

Into the Heart of Q3 Earnings Season

The big banks got us off to a flying start in this Q3 earnings season, but we will get a true sense of how good or otherwise the corporate profitability picture is after seeing the coming week's reporti...

Other symbols:INTCNFLXPGSNAPTSLA
1 day ago - Zacks Investment Research

We're at a very delicate time in this pandemic: FDA advisory panel member

Dr. Ofer Levy, a voting member of the FDA vaccine advisory panel, joins Closing Bell to discuss the panel's decision to recommend a booster dose of Johnson & Johnson's Covid vaccine.

Other symbols:BNTXMRNAPFE
1 day ago - CNBC Television

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA A...

NEW BRUNSWICK, N.J., Oct. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advi...

1 day ago - PRNewsWire

FDA panel backs J&J Covid-19 vaccine booster shot for people 18 years and older

#J&Jvaccine Yahoo Finance's Alexis Christoforous reports the latest FDA decision on COVID-19 boosters. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb...

1 day ago - Yahoo Finance

FDA panel recommends Johnson & Johnson COVID booster for people 18 and up

The advisers unanimously voted that those who got the one-dose vaccine should get a booster at least two months later.

1 day ago - CNET

FDA Advisory Committee Recommends Booster Shots Of J&J Vaccine For People 18 And Older

The recommendation of the independent panel of experts is typically followed by the FDA.

1 day ago - Forbes

Explained here why Johnson & Johnson is setting a $2 billion trust

Johnson & Johnson (NYSE: JNJ) put its obligations for tens of thousands of cases tying talc-based products to cancer into bankruptcy. The company hopes the action will help push a personal injury claims...

1 day ago - Invezz

Could Johnson & Johnson's Booster Opportunity Be Better Than Pfizer's and Moderna's?

The bar could be lower for the FDA to authorize booster shots for J&J's COVID-19 vaccine.

Other symbols:MRNAPFE
1 day ago - The Motley Fool

Johnson & Johnson Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme

CHARLOTTE, N.C., Oct. 14, 2021 /PRNewswire/ -- Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson (NYSE:JNJ) in connection with its defective talc body powder...

1 day ago - PRNewsWire

J&J unit to manage talc claims files for bankruptcy protection

Johnson & Johnson said on Thursday its newly created unit that was established to hold and manage claims in the Baby Powder litigation, has filed for voluntary Chapter 11 bankruptcy protection.

2 days ago - Reuters

Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims

NEW BRUNSWICK, N.J., Oct. 14, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson...

2 days ago - PRNewsWire

FDA advisors prepare to vote on Moderna, J&J Covid boosters

A group of expert FDA advisors plan to meet over the coming days to discuss Moderna's and Johnson & Johnson's applications for a Covid-19 booster. CNBC's Meg Tirrell reports.

Other symbols:MRNA
2 days ago - CNBC Television

J&J Covid-19 Vaccine Recipients May Benefit More From Pfizer Or Moderna Boosters, Study Finds

J&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.

Other symbols:MRNAPFE
2 days ago - Forbes

FDA Says J&J Covid Booster Likely Boosts Immunity, But Evidence Isn't Full-Proof

An advisory panel will review the argument for second Johnson & Johnson doses Friday.

3 days ago - Forbes

3 Top Healthcare Stocks to Buy Right Now

Each has its own reason for being in your portfolio.

Other symbols:FLGTRMD
3 days ago - The Motley Fool

Got $1,000? 2 Super-Smart Stocks That Could Make You Richer Over the Next Decade

Here are two stocks to add to your basket of buys this fall.

Other symbols:ZTS
3 days ago - The Motley Fool

Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals

NEW BRUNSWICK, N.J., Oct. 13, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will hold a Business Review for the investment community on Thursday, November 18, 2021, in which company leaders will sh...

3 days ago - PRNewsWire

Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $157.69, moving -1.6% from the previous trading session.

4 days ago - Zacks Investment Research